Sun Pharma Completes Rs 7,816 Crore Debt Raise via NCDs

Sun Pharmaceutical Industries has raised Rs 7,816 crore through a private placement of rated, unsecured, redeemable, non-convertible debentures (NCDs). The company fully subscribed its base issue of Rs 7,000 crore and exercised a greenshoe option for an additional Rs 816 crore.

Reader Takeaway: Strong capital mobilization via debt; note the 8.05%-8.20% coupon range and five-year maturity profile until 2031.

What just happened

The company issued two distinct series of debentures, both carrying a tenor of 5 years and 1 day, with a scheduled redemption date of 27 October 2031. Series A, valued at Rs 2,003 crore, carries an 8.05% coupon rate, while Series B, valued at Rs 5,813 crore, carries an 8.20% coupon rate. Both series were allotted on 26 October 2026.

Why this matters

For investors, this issuance highlights Sun Pharma’s active management of its capital structure. By securing long-term debt at these rates, the company maintains liquidity for its operational and strategic requirements. The instruments are unsecured, meaning they do not carry a charge over the company’s assets, and they are slated for listing on both the BSE and NSE to provide transparency and potential secondary market liquidity.

Key Terms and Structure

The debentures are structured to balance investor returns with company flexibility. Notably, the Series A debentures include a put option, allowing holders to exercise the right to sell the securities back to the company on 27 March 2028, subject to specific conditions. All debentures are scheduled to be redeemed at par in October 2031.

What to track next

Shareholders should monitor the company’s ongoing capital expenditure plans and how this debt infusion supports their long-term growth initiatives. The listing process on the stock exchanges will be the next formal step for these debt instruments, which will allow for broader market participation.